14th Mar 2008 11:31
Akers Biosciences, Inc.14 March 2008 14 March 2008 Akers Biosciences, Inc. ("ABI" or the "Company") Issue of Equity ABI announces that it has issued a total of 499,056 common shares of nil parvalue each in the Company ("Shares"). 50,623 common shares of nil par value havebeen issued to satisfy payment in lieu of cash for consulting services to theCompany and 448,433 common shares of nil par value have been issued as a resultof the exercise of warrants. Application has been made to the London Stock Exchange for the Shares to beadmitted to trading on AIM, which is expected to take place on 20 March 2008. Following Admission, the Company's enlarged issued share capital will comprise68,554,220 ordinary shares with voting rights. The Company does not hold anyshares in treasury. This figure of 68,554,220 ordinary shares may be used byshareholders in the Company as the denominator for the calculations by whichthey will determine if they are required to notify their interest in, or achange in their interest in, the share capital of the Company under the FSA'sDisclosure and Transparency Rules. Contact: Thomas A. Nicolette +1 856 848 8698President Alasdair Younie +44 (0) 20 7012 2000Arbuthnot Securities Limited END This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
AKR.L